Cancer Vaccines Global Market Report 2026

Cancer vaccines refer to vaccines and medicinal products used in the prevention and treatment of cancer. They help train the immune system to recognize and destroy harmful pathogens and cancerous cells.

The two primary types of cancer vaccines are preventive cancer vaccines and therapeutic cancer vaccines. Therapeutic cancer vaccines assist the immune system in identifying viruses or malignant cells. These vaccines are used for various cancer types such as prostate, cervical, colorectal, throat, and others, and involve multiple technologies including dendritic cell (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole-cell cancer vaccines, viral vectors, and DNA cancer vaccines. They are utilized across sectors such as cancer treatment centers and research institutes.

Tariffs have impacted the cancer vaccines market by increasing the cost of imported biologics, viral vectors, and specialized manufacturing equipment used in vaccine development. Therapeutic cancer vaccines and advanced technologies such as dendritic cell and viral vector vaccines are most affected, particularly in North America and Europe, which rely heavily on cross-border supply chains. These tariffs have raised production costs and slowed commercialization timelines. However, they have also encouraged local manufacturing, regional R&D investments, and strategic partnerships to reduce dependency on imports and strengthen domestic capabilities.

The cancer vaccines market research report is one of a series of new reports from The Business Research Company that provides cancer vaccines market statistics, including cancer vaccines industry global market size, regional shares, competitors with a cancer vaccines market share, detailed cancer vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the cancer vaccines industry. This cancer vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer vaccines market size has grown rapidly in recent years. It will grow from $9.36 billion in 2025 to $10.66 billion in 2026 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to increasing global cancer prevalence, limited effectiveness of conventional cancer treatments, growing awareness of cancer immunotherapy, rising investment in oncology research, early regulatory approvals of cancer vaccines.

The cancer vaccines market size is expected to see rapid growth in the next few years. It will grow to $18.2 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to advancement in vaccine platforms and delivery systems, increasing adoption of personalized cancer vaccines, expansion of clinical pipelines for therapeutic vaccines, growing government funding for cancer research, rising demand for combination cancer therapies. Major trends in the forecast period include rising development of therapeutic cancer vaccines, increasing focus on personalized and targeted immunotherapies, growing clinical trials for novel cancer vaccine technologies, expansion of preventive vaccination programs for cancer prevention, rising collaboration between pharma companies and research institutes.

The increase in government funding for research and development is expected to drive the growth of the cancer vaccines market in the coming years. Government funding refers to financial support provided by public authorities for specific objectives. Investment in research and development is rising as governments seek to stimulate innovation and accelerate the development of new technologies and treatments that address major health and economic challenges. Cancer vaccines support this funding focus by creating opportunities for preventive and therapeutic innovation, thereby encouraging greater financial commitment to vaccine research initiatives. For example, in September 2023, according to the National Cancer Institute, a US-based government agency, the United States Congress allocated a budget of $7.3 billion for fiscal year 2023, representing an increase of $408 million compared with 2022. As a result, rising government investment in research and development is contributing to the expansion of the cancer vaccines market.

Major companies operating in the cancer vaccines market are increasingly concentrating on the introduction of quadrivalent vaccines to strengthen their revenue potential. A quadrivalent vaccine is formulated to protect against four different strains or types of a virus or bacterium. For instance, in January 2023, the Serum Institute of India, an India-based biotechnology company, launched CERVAVAC, the first cervical cancer vaccine developed in India. This vaccine targets human papillomavirus (HPV) types 16 and 18, as well as types 6 and 11, which together are responsible for at least 70% of cervical cancer cases. CERVAVAC is administered as two doses for individuals aged 9-14 years and three doses for those aged 15-26 years.

In August 2024, NEC Bio Therapeutics, a US-based biotechnology company focused on personalized immunotherapies, entered into a collaboration with AGC Biologics to manufacture individualized cancer vaccines. This partnership aims to advance NEC's personalized neoantigen vaccine programs by utilizing AGC Biologics' global manufacturing capabilities, enabling scalable and high-quality production of customized cancer treatments. The collaboration is intended to accelerate clinical development, improve patient access to advanced immunotherapies, and support innovation in the personalized oncology vaccine market.

Major companies operating in the cancer vaccines market are GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

North America was the largest region in the cancer vaccines market in 2025. The regions covered in the cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer vaccines market consists of sales of Bacillus calmette-guerin, Sipuleucel-T, and Human Papillomavirus (HPV) vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Vaccines Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cancer vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
• 2) By Technology: Dendritic Cells (DC) Cancer Vaccines; Recombinant Cancer Vaccines; Antigen/Adjuvant Cancer Vaccines; Whole Cell Cancer Vaccines; Viral Vector & DNA Cancer Vaccines
• 3) By Cancer Type: Prostate; Cervical; Colorectal; Throat; Other Cancer Types
• 4) By End-User: Cancer Treatment Centers; Research Institutes
• Subsegments:
• 1) By Preventive Cancer Vaccines: HPV Vaccines; Hepatitis B Vaccines
• 2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge); Talimogene Laherparepvec (T-VEC); Other Therapeutic Vaccines
• Companies Mentioned: GlaxoSmithKline plc; Merck & Co. Inc.; Aduro Biotech Inc.; AstraZeneca PLC; Dendreon Corporation; Astellas Pharma Inc.; Sanofi SA; Sanpower Group; CSL Limited; Pfizer Inc.; Serum Institute of India Pvt. Ltd.; Advantagene Inc.; Advaxis Inc.; Agenus Inc.; Altor BioScience Corporation; Argos Therapeutics Inc.; Oncothyreon Inc.; Oncovir Inc.; Oxford BioMedica plc.; Prima BioMed Ltd.; Sotio LLC; Transgene SA; Ubivac LLC; Vaccinogen and Vaxon Biotech; Bavarian Nordic A/S; Bharat Biotech International Limited; Bristol-Myers Squibb Company; Dynavax Technologies Corporation; Emergent BioSolutions Inc.; Galena Biopharma Inc.; Moderna Inc.; Biothera Pharmaceuticals Inc.; Celldex Therapeutics Inc.; Genexine Inc.; Gritstone Oncology Inc.; Heat Biologics Inc.; ISA Pharmaceuticals B.V.; Northwest Biotherapeutics Inc.; OncBioMune Pharmaceuticals Inc.; TapImmune Inc.; Vaxil Bio Ltd.; VBI Vaccines Inc.; Ziopharm Oncology Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.